Effect of in utero-administered coumestrol, equol, and organic selenium on biomarkers for phase 2 enzyme capacity and redox status.
The aim of the present study was to investigate the effect of in utero administration of coumestrol, equol, and selenium-enriched yeast on selected hepatic phase 2 enzymes, plasma hormone levels, and markers for redox status in plasma and red blood cells (RBCs). The test compounds were administered via the diet to pregnant Sprague-Dawley rats throughout gestation. Within 24 h following delivery dams and offspring were sacrificed, and blood, liver, and reproductive organs were sampled. Coumestrol, equol, and selenium-enriched yeast did not significantly affect hepatic glutathione S-transferase (GST), quinone reductase (QR), or RBC glutathione peroxidase (GPx) in the offspring, whereas significant increases in GST, QR, and GPx activities in dams were observed following administration of selenium-enriched yeast. The level of 17beta-estradiol in offspring from coumestrol-exposed dams was significantly increased compared with the control. The present results indicate that selenium-enriched yeast, coumestrol, and equol affect selected hepatic phase 2 enzymes and GPx in RBC in dams, whereas the offspring in general were refractive to the employed treatments. Further studies are warranted to investigate whether the observed in utero effects imposed by the selected plant compounds confer permanent alterations on the health status of the animal resulting in an altered resistance to cancer.
Kramer
Franziska
F
Danish Veterinary and Food Administration, IFSE, Mørkhøj Bygade 19, DK-2860 Søborg, Denmark.
Jensen
Pia S
PS
Vinggaard
Anne M
AM
Larsen
Erik H
EH
Breinholt
Vibeke M
VM
D000704:Analysis of Variance; D000818:Animals; D000975:Antioxidants / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology; D015415:Biomarkers / Q000032:analysis; D003375:Coumestrol / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology*; D004798:Enzymes / Q000187:drug effects*; D060754:Equol; D004958:Estradiol / Q000097:blood; D005260:Female; D006728:Hormones / Q000097:blood; D007529:Isoflavones / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology*; D008055:Lipids / Q000097:blood; D008099:Liver / Q000187:drug effects / Q000201:enzymology; D008297:Male; D008315:Malondialdehyde / Q000097:blood; D008431:Maternal-Fetal Exchange / Q000502:physiology*; D009929:Organ Size / Q000187:drug effects; D010084:Oxidation-Reduction / Q000187:drug effects; D010088:Oxidoreductases / Q000187:drug effects*; D011247:Pregnancy; D051381:Rats; D017207:Rats, Sprague-Dawley; D012643:Selenium / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology*; D014599:Uterus / Q000187:drug effects
C007610:4',7-dihydroxy-3,4-dihydroisoflavone; D000975:Antioxidants; D015415:Biomarkers; D004798:Enzymes; D006728:Hormones; D007529:Isoflavones; D008055:Lipids; D004958:Estradiol; D008315:Malondialdehyde; D060754:Equol; D010088:Oxidoreductases; D012643:Selenium; D003375:Coumestrol